Indications
Therapeutic Asset Ratings
6,299 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Baff-R Car-T
Diffuse Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CC
(44)
Belantamab Mafodotin
Monoclonal Gammopathy
Hellenic Society of Hematology
P1/2
CC
(44)
Belantamab Mafodotin
Monoclonal Paraproteinemia Disease
Hellenic Society of Hematology
P1/2
CC
(44)
Bemarituzumab
Cervical Cancer
Centre Leon Berard
P1/2
CC
(44)
Bemarituzumab
Endometrial Carcinoma
Centre Leon Berard
P1/2
CC
(44)
Bemarituzumab
Ovarian Cancer
Centre Leon Berard
P1/2
CC
(44)
Bemarituzumab
Neoplasm
Amgen
P1/2
CC
(44)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)-
Esophageal Cancer
VM Oncology, LLC
P1/2
CC
(44)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)-
Head And Neck Cancer
VM Oncology, LLC
P1/2
CC
(44)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)-
Head And Neck Squamous Cell Carcinoma
VM Oncology, LLC
P1/2
CC
(44)
Bgb-16673
B-Cell Neoplasm
BeOne Medicines
P1/2
CC
(44)
Bicalutamide
Metastatic Neoplasm
Icahn School of Medicine at Mount Sinai
P1/2
CC
(44)
Bicarbonate Ion
Prostate Cancer
University of Washington
P1/2
CC
(44)
BO-112
Non-Small Cell Lung Carcinoma
Clinica Universidad de Navarra, Universidad de Navarra
P1/2
CC
(44)
Bpx-501 T Cells
Hemoglobinopathy
Bellicum Pharmaceuticals
P1/2
CC
(44)
Cambritaxestat
Malignant Pancreatic Neoplasm
iOnctura
P1/2
CC
(44)
Capivasertib
Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
Princess Maxima Center for Pediatric Oncology
P1/2
CC
(44)
cd19-car_lenti t cell
Primary Mediastinal Large B-Cell Lymphoma
Bambino Gesù Hospital and Research Institute
P1/2
CC
(44)
Cetuximab
Biliary Tract Neoplasm
Eli Lilly and Company
P1/2
CC
(44)
Cobolimab
Osteosarcoma
GlaxoSmithKline
P1/2
CC
(44)
Defactinib
Diffuse Glioma, H3 G34 Mutant
Institute of Cancer Research, United Kingdom
P1/2
CC
(44)
Defactinib
Malignant Glioma
Institute of Cancer Research, United Kingdom
P1/2
CC
(44)
Dexasone
Esophageal Cancer
Takeda
P1/2
CC
(44)
Dual-Target Car-Nk Cells
Non-Small Cell Lung Carcinoma
Beijing Biotech
P1/2
CC
(44)
e7386
Melanoma
Eisai Inc.
P1/2
CC
(44)
Showing 3976 to 4000 of 6,299 assets
Previous
Page 160 of 252
Next
